Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: why is the sector like a fishing hole?

August 6, 2018 7:30am

Because the oversold could be biting and a few of last week’s “released” may look appetizing

Who reported last week and on the list of overbought or a possible rebound? Read more …

Pre-open indications: 3 BUY, 2 SELL and 3 trades

Earnings: Monday - Vericel (VCEL), Fate Therapeutics (FATE) and Editas Medicine (EDIT)

Out and about: Regeneron Pharmaceuticals (REGN) and bluebird bio (BLUE) new collaboration applies their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. REGN will make a $100 million investment in BLUE stock at a price of $238.10 per share, which represents a premium of 59% over the $150 closing price on 8/3/18. This approximately $37 million premium will be credited against REGN's initial 50% funding obligation for basic collaboration research, after which the collaborators will fund ongoing research equally.

Are the realities of “our” universe aligned with circumstance; RMi reports pre-open indications that shed light on share pricing events and today’s session values.

When is it wrong to be right so often? Your portfolio should be profiting from RMi’s analysis! Want to know WHY?

Subscribe!

Members only. Please login.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.